FDA approval for novel breast cancer drug granted ahead of anticipated target date
the ONA take:
The US Food and Drug Administration granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer in postmenopausal women whose tumors do not express HER2 protein.
Palbociclib blocks molecules linked to cancer cell growth; it is intended for use in combination with letrozole. Designated as a breakthrough drug in 2014, approval was granted 2 months ahead of its April 13 target date. A 165-patient study showed that palbociclib slowed the progression of breast cancer.
Patients taking palbociclib and letrozole lived 20.2 months on average before their tumors worsened. The most common side effects reported were low white blood cell count, fatigue, nausea, hair loss, diarrhea, vomiting, and nerve damage. The drug is manufactured by Pfizer Inc.
The FDA granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|